Press Release | Neurocrine Biosciences, Inc.

Press Release | Neurocrine Biosciences, Inc.

SPONSOR CONTENT BY NEUROCRINE BIOSCIENCES

New long-term data analyses examine tardive dyskinesia treatment in patients with severe depression, bipolar disorder 

Tardive dyskinesia (TD), a condition characterized by uncontrollable movements of the body, is associated with prolonged use of medications that affect dopamine levels in the brain, such as antipsychotics. This week at the 2018 Annual Psych Congress, Neurocrine Biosciences is presenting new long-term data analyses examining the effects of INGREZZA^® (valbenazine) in patients with mood disorders such as severe depression and bipolar disorder and long-term analyses from RE-KINECT, the largest real-world screening study of patients with possible TD. Learn more here.